BCEL

Atreca, Inc.

0.26 USD
-0.01 (-2.58%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Atreca, Inc. stock is down -13.3% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 February’s closed higher than January. In the last 4 Unusual Options Trades, there were 4 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
12 Jan 18:22 19 Jan, 2024 2.50 PUT 200 1
12 Jan 18:23 19 Jan, 2024 2.50 PUT 200 1
19 Jan 14:39 19 Jan, 2024 2.50 PUT 500 1206
19 Jan 14:56 19 Jan, 2024 2.50 PUT 604 1206

About Atreca, Inc.

Atreca, Inc. discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues.